

C¹ conc'd.

Ar represents: pyridyl which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ alkyl, (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃, and (l) -OCOR¹¹ wherein R¹¹ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR¹⁰ or OCOR¹¹ wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃.

bx 00 750

C²

42. (currently amended) The compound of claim 31, wherein Ar is selected from 3-pyridyl, and 4-pyridyl and R is selected from OCH=C(CH₃)₂, OCH₂CMe=CH₂, OCH₂CH=CH₂ or OCH₂C≡CH.

43. (currently amended) The compound of claim 31, wherein Ar is selected from 3-pyridyl; and 4-pyridyl and R is selected from OH or OCH₂R¹, wherein R¹ is selected from -CH=CMe₂, -CMe=CH₂, -CH=CH₂ and -C≡CH.

47. (currently amended) The compound of claim 31, selected from the group consisting of:

1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;


1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;

1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one; and

1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one.

C³

48. (currently amended) A method of treating cancer in a patient comprising administering to the patient a compound of formula:




or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: pyridyl which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ alkyl, (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃, and (l) -OCOR¹¹ wherein R¹¹ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR¹⁰ or OCOR¹¹ wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃.

49. (currently amended) A method of treating or preventing neoplasms in a patient comprising administering to the patient a compound of formula:




or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: pyridyl which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ alkyl, (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or

C³ *cancel*
different and each represents H or C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃, and (I) - OCOR¹¹ wherein R¹¹ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR¹⁰ or OCOR¹¹ wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃.

54. (currently amended) A method of treating or preventing menopausal disorders and osteoporosis in a patient comprising administering to the patient a compound of formula:



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: pyridyl which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ alkyl, (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃, and (I) - OCOR¹¹ wherein R¹¹ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR¹⁰ or OCOR¹¹ wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃.

A complete listing of the currently pending claims is provided in Appendix B for the Examiners convenience.